Herpes simplex
Drug research and approvals for herpes simplex: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 56 studies of herpes simplex are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and FDA has 1 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 56
- Trials authorized in Canada: 1
- FDA orphan approvals: 1
- EU medicines: 0
Recruiting Now
Newest start dates first, of 56 recruiting on ClinicalTrials.gov ↗- Clinical Trial of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cells)NCT07920172 · Phase 1 / Phase 2 · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · starts Nov 10, 2026
- Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) PainNCT07732556 · Not applicable · Tanta University · starts Jul 1, 2026
- Subcutaneous Calcitonin in Acute Herpes ZosterNCT07655804 · Phase 3 · Tanta University · starts Jul 1, 2026
- Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AboveNCT07817108 · Phase 3 · Suzhou Abogen Biosciences Co., Ltd. · starts Jun 27, 2026
- Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic DiseasesNCT07341386 · Phase 4 · University of Sao Paulo General Hospital · starts Jun 25, 2026
- Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After…NCT07076498 · Phase 1 · M.D. Anderson Cancer Center · starts Apr 23, 2026
- Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and…NCT07308886 · Phase 2 · National Cancer Institute (NCI) · starts Apr 8, 2026
- A Phase I/IIa Study of C5252 in Patients With Intracranial TumorNCT07243340 · Phase 1 / Phase 2 · ImmVira Pharma Co. Ltd · starts Apr 3, 2026
- A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population…NCT07502560 · Phase 4 · GlaxoSmithKline · starts Mar 31, 2026
- Long-term Effectiveness of the Live Attenuated Herpes Zoster VaccineNCT07585370 · Not reported · Jiangsu Province Centers for Disease Control and Prevention · starts Mar 6, 2026
Drug Pipeline
4 approved, 5 in phase 3, 6 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Acyclovir, Dexamethasone phosphoric acid, Dexamethasone, Trifluridine
- Valacyclovir
- Phase 3 Human herpesvirus 1 DNA polymerase inhibitor
- Foscarnet
- Phase 3 Human herpesvirus 1 DNA polymerase inhibitor
- Famciclovir
- Phase 3 Human herpesvirus 1 DNA polymerase inhibitor
- Amenamevir
- Phase 3 Helicase primate complex inhibitor
- Vidarabine
- Phase 3 Human herpesvirus 1 DNA polymerase inhibitor
- Docosanol
- Phase 2 Envelope glycoprotein inhibitor
- Glutamine
- Phase 2 Unknown
- Fialuridine
- Phase 2
- Glycine
- Phase 2
- QS-21
- Phase 2
- Edetic acid
- Phase 2
- Cidofovir anhydrous
- Phase 1 Human herpesvirus 1 DNA polymerase inhibitor
- Aspirin
- Phase 1 Cyclooxygenase inhibitor
- Pritelivir
- Phase 1 Helicase/primase inhibitor
How Its Trials Ended
316 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 89 whose ending is known, 61% met their primary endpoint, 11% missed it and 28% stopped early.
- Completed, result not reported15248%
- Met its primary endpoint5417%
- Ongoing4615%
- Status unknown299%
- Stopped: other or unclear113%
- Missed its primary endpoint103%
- Stopped: enrollment or feasibility62%
- Stopped: sponsor or business decision52%
- Stopped: lack of efficacy31%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Aug 31, 2022 | A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of…Pritelivir / probenecid | AiCuris Anti-Infective Cures | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Mar 29, 2019 | AvaclyrAVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes… | Fera Pharmaceuticals | Approved |
| Jun 25, 2025 | Granzyme B associated peptideTreatment of herpes simplex encephalitis (HSE) | BioJENC, LLC. | Designated |
| Jun 24, 2022 | HSV-1-erasing lentivirus-like particle delivering…Treatment of herpes simplex (HSV-1) infected keratitis (HSK) | Hangzhou BDgene Co., Ltd. | Designated |
| May 29, 1990 | PR-225 (redox-acyclovir)Treatment of herpes simplex encephalitis in individuals afflicted with AIDS. | Pharmos | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA